Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels

Purpose: The aim of the study was to evaluate the severity of systemic responses to trauma; and thus, to determine the most advantageous timing for surgery among different phases of the menstrual cycle. Materials and Methods: 99 women were included in this study. They were patients who were in the postmenopausal period and patients in the different menstrual cycle phases of the premenopausal period. C-reactive protein, interleukin-1β, interleukin-6 and tumor necrosis factor-α levels were measured before and after surgery. Results: Among the menstrual cycle phases, the highest increases in the concentrations of IL-6 and TNF-α during the postoperative period were found in follicular phase patients. Luteal phase patients showed the lowest increases in interleukin-1β and interleukin-6 levels. TNF-α and CRP levels were increased significantly in all phases but not in the luteal phase. Conclusion: Timing of surgery in premenopausal patients seems effective on systemic inflammatory responses to trauma. Performing the operation based on the timing of the menstrual cycle will minimize the risk of operative trauma among premenopausal patients. This may be beneficial for their well-being.

Breast cancer; Menstrual cycle; Surgery timing; Systemic responses to trauma

[1] Samuel M., Wai K.L., Brennan V.K., Yong W.S.: “Timing of breast surgery in premenopausal breast cancer patients”. Cochrane Database Syst. Rev., 2011, 5, 2.

[2] Dağlı E., Altunkan A.A., Birbiçer H., Temel G.O.: “Comparison of PCT, CRP, D­Dimer, lactate, TNF­α, IL­1β, IL­6 and lL­ 10 in

development of systemic inflammatory response syndrome and sep­ sis on patients with isolated head trauma and polytrauma”. Turk. J. Intense. Care., 2012, 10, 117.

[3] Hrushesky W.J., Bluming A.Z., Gruber S.A., Sothern R.B.: “Men­ strual influence on surgical cure of breast cancer”. Lancet, 1989, 2, 949.

[4] Yu H.P., Chaudry I.H.: “The role of estrogen and receptor agonists in maintaining organ function after trauma­hemorrhage”. Shock, 2009, 31, 227.

[5] Hsieh Y.C., Yu H.P., Suzuki T., Choudhry M.A., Schwacha M.G., Bland K.I., et al.: “Upregulation of mitochondrial respiratory com­ plex IV by estrogen receptor–beta is critical for inhibiting mitochon­ drial apoptotic signaling and restoring cardiac functions following trauma­hemorrhage”. J. Mol. Cell. Cardiol., 2006, 41, 511.

[6] Lavine J.A., Farnoodian M., Wang S., Darjatmoko S.R., Wright L.S., Gamm D.M., et al.: “β_2­adrenergic receptor antagonism at­ tenuates CNV through inhibition of VEGF and IL­6 expression”. Invest. Ophthalmol Vis. Sci., 2017, 58, 299.

[7] Svoboda P., Kantorová I., Ochmann J.: “Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients”. J. Trauma, 1994, 36, 336.

[8] Zabihi M., Hajhashemi V., Talebi A., Minaiyan M.: “Evaluation of central and peripheral effects of doxepin on acetic acid­ induced colitis in rat and the involved mechanisms”. EXCLI. J., 2017, 16, 414.

[9] Heikkilä K., Ebrahim S., Lawlor D.A.: “A systematic review of the association between circulating concentrations of C reactive protein and cancer”. J. Epidemiol Community Health, 2007, 61, 824.

[10] Santonocito C., De Loecker I., Donadello K., Moussa M.D., Markowicz S., Gullo A., et al.: “C­reactive protein kinetics after major surgery”. Anesth. Analg., 2014, 119, 624.

[11] Mostafa G., Huynh T., Sing R.F., Miles W.S., Norton H.J., Thoma­ son M.H.: “Gender­related outcomes in trauma”. J. Trauma., 2002, 53, 430.

[12] Gannon C.J., Pasquale M., Tracy J.K., McCarter R.J., Napolitano L.M.: “Male gender is associated with increased risk for postinjury pneumonia”. Shock, 2004, 21, 410.

[13] Frink M., Pape H.C., van Griensven M., Krettek C., Chaudry I.H., Hildebrand F.: “Influence of sex and age on mods and cytokines after multiple injuries”. Shock, 2007, 27, 151.

[14] Gameiro C.M., Romão F., Castelo­Branco C.: “Menopause and ag­ ing: changes in the immune system ­ a review”. Maturitas, 2010, 67, 316.

[15] Yasui T., Maegawa M., Tomita J., Miyatani Y., Yamada M., Uemura H., et al.: “Changes in serum cytokine concentrations during the menopausal transition”. Maturitas, 2007, 56, 396.

[16] Endrighi R., Hamer M., Steptoe A.: “Post­menopausal women exhibit greater interleukin­6 responses to mental stress than older men”. Ann. Behav. Med., 2016, 50, 564.

[17] Grant C.S., Ingle J.N., Suman V.J., Dumesic D.A., Wickerham D.L., Gelber R.D., et al.: “Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study”. J. Clin. Oncol., 2009, 27, 3620.

[18] Powles T.J., Jones A.L., Ashley S., Tidy A., Kissin M.W., Gelber R.D., et al.: “Menstrual effect on surgical cure of breast cancer”. Lancet, 1989, 2, 1343.

[19] Veronesi U., Luini A., Mariani L., Del Vecchio M., Alvez D., An­ dreoli C., et al.: “Effect of menstrual phase on surgical treatment of breast cancer”. Lancet, 1994, 343, 1545.

[20] Thorpe H., Brown S.R., Sainsbury J.R., Perren T.J., Hiley V., Dowsett M., et al.: “Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3­year prognosis: the ITS Study”. Br. J. Cancer, 2008, 98, 39.

[21] Wood P.A., Hrushesky W.J.: “Sex cycle modulates cancer growth”. Breast Cancer Res. Treat., 2005, 91, 95.

[22] Liu Y., Wang Y., Zhou L., Yin K., Yin W., Lu J.: “Prognostic effect of menstrual cycle on timing of surgery in premenopausal breast cancer patients”. Am. J. Surg., 2015, 210, 506.

[23] Suzuki T., Shimizu T., Yu H.P., Hsieh Y.C., Choudhry M.A., Schwacha M.G., et al.: “Tissue compartment–specific role of estro­ gen receptor subtypes in immune cell cytokine production following trauma­hemorrhage”. J. Appl. Physiol., 2007, 102, 163.

[24] Suzuki T., Shimizu T., Yu H.P., Hsieh Y.C., Choudhry M.A., Chaudry I.H.: “Salutary effects of 17betaestradiol on T­cell signal­ ing and cytokine production after trauma­hemorrhage are mediated primarily via estrogen receptor–alpha”. Am. J. Physiol. Cell. Phys­ iol., 2007, 292, C2103.

[25] Jatoi I.: “Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis”. Breast Cancer Res. Treat., 1998, 52, 217.

[26] Hoff J.D., Quigley M.E., Yen S.S.C.: “Hormonal dynamics at mid­ cycle: a reevaluation”. J. Clin. Endocrinol. Metab., 1983, 57, 792.